169 related articles for article (PubMed ID: 34494245)
1. Proteomic biomarkers of non-small cell lung cancer patients.
Baran K; Brzeziańska-Lasota E
Adv Respir Med; 2021; 89(4):419-426. PubMed ID: 34494245
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer.
Hu R; Huffman KE; Chu M; Zhang Y; Minna JD; Yu Y
J Proteome Res; 2016 Feb; 15(2):477-86. PubMed ID: 26736068
[TBL] [Abstract][Full Text] [Related]
3. Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer.
Marrugal Á; Ojeda L; Paz-Ares L; Molina-Pinelo S; Ferrer I
Dis Markers; 2016; 2016():2138627. PubMed ID: 27445423
[TBL] [Abstract][Full Text] [Related]
4. Proteomic analysis of non-small cell lung cancer tissue interstitial fluids.
Li S; Wang R; Zhang M; Wang L; Cheng S
World J Surg Oncol; 2013 Aug; 11():173. PubMed ID: 23914992
[TBL] [Abstract][Full Text] [Related]
5. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer.
Ostroff RM; Bigbee WL; Franklin W; Gold L; Mehan M; Miller YE; Pass HI; Rom WN; Siegfried JM; Stewart A; Walker JJ; Weissfeld JL; Williams S; Zichi D; Brody EN
PLoS One; 2010 Dec; 5(12):e15003. PubMed ID: 21170350
[TBL] [Abstract][Full Text] [Related]
6. SWATH™- and iTRAQ-based quantitative proteomic analyses reveal an overexpression and biological relevance of CD109 in advanced NSCLC.
Zhang F; Lin H; Gu A; Li J; Liu L; Yu T; Cui Y; Deng W; Yan M; Li J; Yao M
J Proteomics; 2014 May; 102():125-36. PubMed ID: 24667143
[TBL] [Abstract][Full Text] [Related]
7. Proteomics biomarkers for non-small cell lung cancer.
Kisluk J; Ciborowski M; Niemira M; Kretowski A; Niklinski J
J Pharm Biomed Anal; 2014 Dec; 101():40-9. PubMed ID: 25175018
[TBL] [Abstract][Full Text] [Related]
8. Proteomic biomarkers for lung cancer progression.
Ren Y; Zhao S; Jiang D; Feng X; Zhang Y; Wei Z; Wang Z; Zhang W; Zhou QF; Li Y; Hou H; Xu Y; Zhou F
Biomark Med; 2018 Mar; 12(3):205-215. PubMed ID: 29424557
[TBL] [Abstract][Full Text] [Related]
9. TNF receptor-associated factor 1 as a biomarker for assessment of non-small cell lung cancer metastasis and overall survival.
Wen X; Wang B; Feng T; Yuan W; Zhou J; Fang T
Clin Respir J; 2018 Jul; 12(7):2197-2203. PubMed ID: 29528567
[TBL] [Abstract][Full Text] [Related]
10. Tumor-derived exosomal proteins as diagnostic biomarkers in non-small cell lung cancer.
Niu L; Song X; Wang N; Xue L; Song X; Xie L
Cancer Sci; 2019 Jan; 110(1):433-442. PubMed ID: 30407700
[TBL] [Abstract][Full Text] [Related]
11. The clinical and prognostic significance of YWHAZ in non-small-cell lung cancer patients: Immunohistochemical analysis.
Deng Y; Zheng J; Ma J
J Cell Biochem; 2019 Apr; 120(4):6290-6298. PubMed ID: 30378158
[TBL] [Abstract][Full Text] [Related]
12. Identification of GlcNAcylated alpha-1-antichymotrypsin as an early biomarker in human non-small-cell lung cancer by quantitative proteomic analysis with two lectins.
Jin Y; Wang J; Ye X; Su Y; Yu G; Yang Q; Liu W; Yu W; Cai J; Chen X; Liang Y; Chen Y; Wong BH; Fu X; Sun H
Br J Cancer; 2016 Mar; 114(5):532-44. PubMed ID: 26908325
[TBL] [Abstract][Full Text] [Related]
13. HSP90B1 overexpression predicts poor prognosis in NSCLC patients.
Xu Y; Chen Z; Zhang G; Xi Y; Sun R; Wang X; Wang W; Chai F; Li X
Tumour Biol; 2016 Oct; 37(10):14321-14328. PubMed ID: 27599983
[TBL] [Abstract][Full Text] [Related]
14. Proteomic and genomic biomarkers for Non-Small Cell Lung Cancer: Peroxiredoxin, Haptoglobin, and Alpha-1 antitrypsin.
Najafi Z; Mohamadnia A; Ahmadi R; Mahmoudi M; Bahrami N; Khosravi A; Jamaati H; Tabarsi P; Kazem Pour Dizaji M; Shirian S
Cancer Med; 2020 Jun; 9(11):3974-3982. PubMed ID: 32232956
[TBL] [Abstract][Full Text] [Related]
15. Depleting PTOV1 sensitizes non-small cell lung cancer cells to chemotherapy through attenuating cancer stem cell traits.
Wu Z; Liu Z; Jiang X; Mi Z; Meng M; Wang H; Zhao J; Zheng B; Yuan Z
J Exp Clin Cancer Res; 2019 Aug; 38(1):341. PubMed ID: 31387622
[TBL] [Abstract][Full Text] [Related]
16. HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer.
Zhang J; Chen N; Qi J; Zhou B; Qiu X
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1441-9. PubMed ID: 24770635
[TBL] [Abstract][Full Text] [Related]
17. Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis.
Tan F; Jiang Y; Sun N; Chen Z; Lv Y; Shao K; Li N; Qiu B; Gao Y; Li B; Tan X; Zhou F; Wang Z; Ding D; Wang J; Sun J; Hang J; Shi S; Feng X; He F; He J
Mol Cell Proteomics; 2012 Feb; 11(2):M111.008821. PubMed ID: 22064513
[TBL] [Abstract][Full Text] [Related]
18. miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke.
Babu N; Advani J; Solanki HS; Patel K; Jain A; Khan AA; Radhakrishnan A; Sahasrabuddhe NA; Mathur PP; Nair B; Keshava Prasad TS; Chang X; Sidransky D; Gowda H; Chatterjee A
Microrna; 2018; 7(1):38-53. PubMed ID: 29299995
[TBL] [Abstract][Full Text] [Related]
19. Biomarker discovery in highly invasive lung cancer cell through proteomics approaches.
Kuo CH; Lin MW; Hsu YW; Chou HC; Lin LH; Law CH; Lin YC; Hu RY; Kuo WH; Ko ML; Chang SJ; Lee YR; Chan HL
Cell Biochem Funct; 2021 Apr; 39(3):367-379. PubMed ID: 33135206
[TBL] [Abstract][Full Text] [Related]
20. mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry.
Wang L; Yue W; Zhang L; Zhao X; Wang Y; Xu S
Surg Today; 2012 May; 42(5):419-25. PubMed ID: 22127531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
